Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Tesla solar panels ignited at an Amazon warehouse in Redlands, California in June 2018, Bloomberg reports. The news comes days after Walmart sued Tesla for at least 7 fires...Technologyread more
The death comes as federal and state health officials investigate a slew of lung illnesses in connection to e-cigarette use.Health and Scienceread more
This week Jim Cramer has been on a search for the next generation of biotech companies, the ones that shot through the roof in 2014 and could be the best play for 2015.
This weekend, the big-dog specialty biopharmaceutical company Shire announced that it will acquire NPS Pharmaceuticals, at a 51 percent premium to where it was trading before. NPS is a developer of orphan drugs that treat ultra-rare diseases.
If there is one thing that the Shire acquisition tells Cramer, it is that big pharma has finally figured out that there is enormous value potential available in companies within the orphan drug space.
One of those companies is BioMarin, which is widely considered the top orphan drug developer. It helps to develop enzyme replacement therapies for rare genetic diseases.
In Cramer's perspective, BioMarin has the strongest pipeline of orphan drugs that exist. It also announced on Thursday that it would acquire Prosensa for $840 million. Prosensa sports a drug treatment for the fatal genetic condition Duchenne muscular dystrophy.
BioMarin upped its guidance for 2015, indicating that it is confident with what's in the pipeline. The "Mad Money" host spoke with company CEO Jean-Jacques Bienaime to find out more.
"The launch is going better than we anticipated around the world. The feedback we are getting from clinicians and patients about the benefits they are observing with the drug is very positive," said Bienaime.
With big pharma recognizing the value of orphan drug companies, Cramer worries about the ability for a company like BioMarin to stay independent. The CEO commented on the staying power of BioMarin and its opportunity for growth in the next five years.
"We have been managing this company to grow and stay independent. We have growing revenues; we will soon report 2014 revenues of over $700 million. We believe that we will reach $1 billion in revenues in the next two to three years."
Read more from Mad Money with Jim Cramer
Cramer Remix: Coke, Pepsi or Monster?
Cramer: The cause of the commodity collapse
Cramer: Low Treasury rates are good for you
BioMarin has gained 41 percent since Cramer last spoke with the CEO in September. However, Cramer also agrees that there is more value to come.
In the context of how Shire valued NPS, Cramer estimated that BioMarin could be worth $22 billion—significantly higher than its current $14.4 billion market cap.